AstraZeneca shares phase 3 results for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
AstraZeneca shares phase 3 results for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
Gilead opens new research centre bringing together oncology, inflammation and research data science teams
The centre in California supports the company’s $32bn US investment
CPHI Milan introduces new specialist zones
The event runs from 6-8 October 2026 at the Fiera Milano exhibition centre in Rho, Italy
Latest content
Langland appoints Kathryn Stewart as Head of Strategy and promotes Diane Ross to Head of Scientific Practice
Stewart previously held roles at Saatchi & Saatchi Health London, part of the Publicis Health network, and Avalere, while Ross has been part of Publicis Health for over two decades
Read More
Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory
Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK
Read More
Abivax has appointed Ivan Nuñez-Pacheco as Abivax Global Head of Patient Services
Nuñez-Pacheco most recently served as Senior Director of AbbVie Patient Services
Read More
Abivax has appointed James Berger as Global Head of Marketing
Berger previously served in senior leadership roles at Amgen and Takeda
Read More
Intelligence
Cell and gene therapies – moving from niche innovations towards broader clinical use
Looking at the regulatory challenges of cell and gene therapies for serious or life-threatening rare diseases
Read More
Creating a strong patent portfolio through constant communication
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read More
Leading through complexity
Strengthening strategic judgement during uncertainty – exploring the strategic concepts that matter most
Read More
The Amazon reckoning: GLP-1s and the consumer lifestyle shift – why the molecule is no longer enough
Amazon’s entry into the GLP-1 market should be a signal to pharma that it needs to shift focus from molecule to ‘Operating Model’
Read More
Lupus – moving patient care beyond current therapies towards resetting the immune system
Precision medicine is no longer theoretical, but increasingly achievable for people living with lupus
Read More
Forging a connection through creativity
A spark of creativity can cut through complexity, adding real value and helping to forge true connections with patients
Read More
Blogs
Latest
Changing the narrative: why hidden struggles matter
September 10, 2026 | Mednet|Making Health Whole, Medical Communications, Suicide Prevention, healthcare innovation, whole health
On Suicide Prevention Day, we’re focusing on something often overlooked: the difference between what’s visible and what’s actually being carried. Many people living with long-term …
From Booth to Bavaria: A Recap of Impact at ESC 2026
September 7, 2026 | Medscape Education|CME, Cardiology Education, IME, Patient Impact, cardiology
We have officially wrapped up another year at ESC. For Medscape Education, 4 days on the ground confirmed what 3 decades of cardiovascular education have …
Supporting the people who support patients
August 28, 2026 | Mednet|Making Health Whole, Whole Health Communication, carers, healthcare communications
Supporting those who provide care can lead to improved experiences and health outcomes for everyone involved.
NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement
August 27, 2026 | Impetus Digital|AI, AI pharma, AI tools, Compliant AI, Impetus Digital, QIP, Quality improvement programs, artificial intelligence, compliance, insight gathering, medical education, pharma insights, pharma teams, pharma webinar, training programs, virtual tools
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards
Real Chemistry Deepens German Market Expertise with Appointment of Dirk Poschenrieder as Managing Director, Germany
August 25, 2026 | Real Chemistry|BusinessGrowth, Germany, emea, healthcarecommunications
Senior hire strengthens Real Chemistry’s ability to help healthcare clients connect global strategy to nuanced needs for in-market execution
Intelligent Commercialization™ across the pharma lifecycle
August 27, 2026 | Inizio|Intelligent Commercialization, Pharma, healthcare
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
Four steps to a smarter congress strategy: A practical guidebook
August 27, 2026 | Inizio|Intelligent Congress, Pharma, healthcare
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Permission to pause: making treatment breaks part of the cancer care conversation
August 5, 2026 | Cuttsy + Cuttsy|Cancer, Social Listening, Treatment breaks, Treatment pause, oncology
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
July 24, 2026 | Cuttsy + Cuttsy|EU HTA, Patient involvement, clinical trials, design
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at …
Infographic: Are data blind spots putting your launch at risk?
July 16, 2026 | Inizio|AI, Pharma, Product Launch, healthcare
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult …
Reimagine health with Inizio.
August 19, 2025 | Inizio | healthcare